Selected publications

1. Nguyen PM, Dagley LF, Preaudet A, Lam N, Giam M, Fung KY, Aizel K, van Duijneveldt G, Tan CW, Hirokawa Y, Yip HYK, Love CG, Poh AR, Cruz A, Burstroem C, Feltham R, Abdirahman SM, Meiselbach K, Low RRJ, Palmieri M, Ernst M, Webb AI, Burgess T, Sieber OM, Bouillet P, Putoczki TL. Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer. Cell Death Differ, 2019 Jul 11. doi: 10.1038/s41418-019-0383-9. PMID: 31296963
2. Jorissen RN, Croxford M, Jones IT, Ward RL, Hawkins NJ, Gibbs P, Sieber OM. Evaluation of the Transferability of Survival Calculators for Stage II/III Colon Cancer Across Healthcare Systems. Int J Cancer. 2019 Jul 1;145(1):132-142. PMID: 30620048
3. Tan FH, Putoczki TL, Lou J, Hinde E, Hollande F, Giraud J, Stylli SS, Paradiso L, Zhu HJ, Sieber OM, Luwor RB. Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers (Basel). 2018 Dec 19;10(12). PMID: 30572654
4. Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC*, Tomlinson I*. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 2018 Sep;3(9):635-643. PMID: 30042065
5. Sakthianandeswaren A, Parsons MJ, Mouradov D, MacKinnon RN, Catimel B, Liu S, Palmieri M, Love C, Jorissen RN, Li S, Whitehead L, Putoczki TL, Preaudet A, Tsui C, Nowell CJ, Ward RL, Hawkins NJ, Desai J, Gibbs P, Ernst M, Street I, Buchert M, Sieber OM. MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors, Cancer Discov. 2018 Aug;8(8):988-1005. PMID: 29880585
6. Eissmann MF, Dijkstra C, Wouters MA, Baloyan D, Mouradov D, Nguyen PM, Davalos-Salas M, Putoczki TL, Sieber OM, Mariadason JM, Ernst M, Masson F. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner. Cancer Immunol Res. 2018 Apr;6(4):409-421. PMID: 29463593
7. Williams DS, Mouradov D, Jorissen RN, Newman MR, Amini E, Nickless DK, Teague JA, Fang CG, Palmieri M, Parsons MJ, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Faragher I, Jones I, Gibbs P, Sieber OM. Lymphocytic response to tumor and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2018 Jan 30. pii: gutjnl-2017-315664. PMID: 29382774
8. Tögel L, Nightingale R, Wu R, Chüeh AC, Al-Obaidi S, Luk I, Dàvalos-Salas M, Chionh F, Murone C, Buchanan DD, Sieber O, Arango D, Tebbutt NC, Williams D, Dhillon A, and Mariadason JM, DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Sci Rep. 2018 Jan 29;8(1):1767. PMID: 29379130
9. Wang J, Mouradov D, Wang X, Jorissen RN, Chambers MC, Zimmerman LJ, Vasaikar S, Love CG, Li S, Lowes K, Leuchowius KJ, Jousset H, Weinstock J, Yau C, Mariadason J, Shi Z, Ban Y, Chen X, Coffey RJC, Slebos RJC, Burgess AW, Liebler DC, Zhang B, Sieber OM. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology. 2017 Jun 15. pii: S0016-5085(17)35742-6. PMID: 28625833
10. Poh AR, Love CG, Masson F, Preaudet A, Tsui C, Whitehead L, Monard S, Khakham Y, Burstroem L, Lessene G, Sieber O, Lowell C, Putoczki TL, O'Donoghue RJ, Ernst M. Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell. 2017 Apr 10;31(4):563-575.e5. PMID: 28399411

Additional publications